| Name | Medicap Pharmacy |
|---|---|
| Organization Name | Glenpool Pharmacy Inc |
| Location | 262 E 141st St, Glenpool, Oklahoma 74033 |
| Type | Pharmacy |
| Phone | (918) 322-3667 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Overall rates of cancer death for both men and women have declined in the United States, and cancer incidence has remained stable among men. However, overall cancer incidence among women has increased slightly, according to a special article that appears in the October 5 issue of the Journal of the National Cancer Institute.
The American Association of Critical-Care Nurses (AACN) has selected six Indianapolis hospitals as the initial participants to launch its hospital-based nurse leadership and innovation training program.
Research-clinicians at Children's National Health System led the first study to identify a promising treatment to reduce or prevent brain injury in newborns who have suffered hypoxia-ischemia, a serious complication in which restricted blood flow deprives the brain of oxygen.
Inspired by tiny particles that carry cholesterol through the body, MIT chemical engineers have designed nanoparticles that can deliver snippets of genetic material that turn off disease-causing genes.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
› Verified 5 days ago
| NPI Number | 1750440129 |
| Organization Name | GLENPOOL PHARMACY INC |
| Doing Business As | MEDICAP PHARMACY |
| Type | Pharmacy |
| Address | 262 E 141st Street, Glenpool, OK 74033 |
| Phone Number | 918-322-3667 |
News Archive
Overall rates of cancer death for both men and women have declined in the United States, and cancer incidence has remained stable among men. However, overall cancer incidence among women has increased slightly, according to a special article that appears in the October 5 issue of the Journal of the National Cancer Institute.
The American Association of Critical-Care Nurses (AACN) has selected six Indianapolis hospitals as the initial participants to launch its hospital-based nurse leadership and innovation training program.
Research-clinicians at Children's National Health System led the first study to identify a promising treatment to reduce or prevent brain injury in newborns who have suffered hypoxia-ischemia, a serious complication in which restricted blood flow deprives the brain of oxygen.
Inspired by tiny particles that carry cholesterol through the body, MIT chemical engineers have designed nanoparticles that can deliver snippets of genetic material that turn off disease-causing genes.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
› Verified 5 days ago
| NPI Number | 1871823781 |
| Organization Name | GLENPOOL PHARMACY INC |
| Doing Business As | MEDICAP PHARMACY |
| Type | Pharmacy |
| Address | 1601 N Peoria Ave, Tulsa, OK 74106 |
| Phone Number | 918-322-3667 |
News Archive
Overall rates of cancer death for both men and women have declined in the United States, and cancer incidence has remained stable among men. However, overall cancer incidence among women has increased slightly, according to a special article that appears in the October 5 issue of the Journal of the National Cancer Institute.
The American Association of Critical-Care Nurses (AACN) has selected six Indianapolis hospitals as the initial participants to launch its hospital-based nurse leadership and innovation training program.
Research-clinicians at Children's National Health System led the first study to identify a promising treatment to reduce or prevent brain injury in newborns who have suffered hypoxia-ischemia, a serious complication in which restricted blood flow deprives the brain of oxygen.
Inspired by tiny particles that carry cholesterol through the body, MIT chemical engineers have designed nanoparticles that can deliver snippets of genetic material that turn off disease-causing genes.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
› Verified 5 days ago
News Archive
Overall rates of cancer death for both men and women have declined in the United States, and cancer incidence has remained stable among men. However, overall cancer incidence among women has increased slightly, according to a special article that appears in the October 5 issue of the Journal of the National Cancer Institute.
The American Association of Critical-Care Nurses (AACN) has selected six Indianapolis hospitals as the initial participants to launch its hospital-based nurse leadership and innovation training program.
Research-clinicians at Children's National Health System led the first study to identify a promising treatment to reduce or prevent brain injury in newborns who have suffered hypoxia-ischemia, a serious complication in which restricted blood flow deprives the brain of oxygen.
Inspired by tiny particles that carry cholesterol through the body, MIT chemical engineers have designed nanoparticles that can deliver snippets of genetic material that turn off disease-causing genes.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
› Verified 5 days ago
Medicap Pharmacy Type: Pharmacy Location: 262 E 141st St, Glenpool, Oklahoma 74033 Phone: (918) 322-3667 | |
Pros Type: DME Supplier - Customized Equipment Location: 480 E 141st St, Glenpool, Oklahoma 74033 Phone: (918) 518-5980 |